Highlights AnGes, Inc.

Equities

4563

JP3127700007

Delayed Japan Exchange Other stock markets 23:41:37 2024-05-27 EDT			5-day change	1st Jan Change
46 ^JPY	0.00%		0.00%	-36.11%

01-19	Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	MT
01-18	Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	01-19	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	01-18	CI
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study	11-14	CI
AnGes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Eiger Biopharmaceuticals Inc. and AnGes Inc. Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® in Japan	22-05-10	CI
Etsy, Inc: Great opportunity or distorted reality?	22-01-31
AnGes, Inc. Announces Results of Phase 1/2 and Phase 2/3 Clinical Trials	21-11-05	CI
AnGes, Inc. completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others.	20-12-14	CI
AnGes, Inc. signed an agreement to acquire Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others for approximately $110 million.	20-11-08	CI
AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey	20-10-15	CI
AnGes, Inc. and Brickell Biotech, Inc. Announce Collaboration Agreement for the Development of A Novel DNA Vaccine Candidate for COVID-19 in the U.S	20-09-08	CI
Japanese shares extend falls as coronavirus worries persist	20-07-17	RE
AnGes, Inc. Completes Enrollment for Phase 1/2A Clinical Trial of DNA Vaccine for Hypertension	20-04-30	CI
Anges, Inc. Provides Update on Joint Development Between Osaka University and Anges for DNA Vaccine Targeting Novel Coronavirus	20-04-30	CI
AnGes, Inc. Enters into Co-Development Agreement with Osaka University	20-03-05	CI
AnGes, Inc. Announces Completion of Enrollment in its Phase Ib Clinical Trial of NF-B Decoy Oligo DNA for Chronic Discogenic Lumbar Back Pain in the United States	20-02-27	CI
AnGes, Inc. Announces Consolidated Earnings Results for the First Nine Months Ended September 30, 2019; Provides Earnings Guidance for the Full Year Ending December 31, 2019	19-10-27	CI
AnGes, Inc. Reports Consolidated Earnings Results for the Second Quarter Ended June 30, 2019; Provides Earnings Guidance for Year Ending December 31, 2019	19-07-28	CI
AnGes, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2019	19-04-22	CI
Anges, Inc. and Mitsubishi Tanabe Pharma Corporation Obtain Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia	19-04-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AnGes, Inc.

Equities

4563

JP3127700007

Highlights

Filters